Zentalis stock hits 22-month high on ovarian cancer data

Zentalis (ZNTL) stock soared 40% to a 22-month high after its ovarian cancer drug showed superior efficacy at a 400 mg dose. Guggenheim raised its price target to $10, maintaining a 'Buy' rating with 56% upside. The firm selected the higher dose for Phase 2 and 3 trials following positive interim results.